Quarterly report pursuant to Section 13 or 15(d)

Impact of COVID-19 (Details)

v3.21.1
Impact of COVID-19 (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Unusual or Infrequent Item, or Both [Line Items]      
Total revenues $ 545,165   $ 211,466
Genomic Test      
Unusual or Infrequent Item, or Both [Line Items]      
Change in testing volume (as a percent) 10.30%    
Routine Clinical Test      
Unusual or Infrequent Item, or Both [Line Items]      
Change in testing volume (as a percent) (6.80%)    
Transfer of intellectual property and other      
Unusual or Infrequent Item, or Both [Line Items]      
Total revenues $ 4,269   9,553
Services      
Unusual or Infrequent Item, or Both [Line Items]      
Increase in revenue 336,100    
Total revenues 506,951   $ 170,839
CMS Accelerated and Advanced Payment Program, COVID-19      
Unusual or Infrequent Item, or Both [Line Items]      
Proceeds from issuance of debt   $ 14,000  
Distribution to Healthcare Providers, COVID-19      
Unusual or Infrequent Item, or Both [Line Items]      
Proceeds from issuance of debt 16,200    
Distribution to Healthcare Providers, COVID-19 | Transfer of intellectual property and other      
Unusual or Infrequent Item, or Both [Line Items]      
Total revenues $ 16,200